Combination Immunotherapy and Chemotherapy Used in GI Cancers

home / case-based-roundtable-series / combination-immunotherapy-and-chemotherapy-used-in-gi-cancers

This roundtable series explores combination treatments for patients with upper gastrointestinal cancer, as discussed by key opinion leaders and participants at virtual live events.

CheckMate 649 Study in GI Cancers Shows Survival Benefit for Nivolumab/Chemotherapy

Jaffer A. Ajani, MD

October 31st 2022

Jaffer A. Ajani, MD, discusses the design and results of the CheckMate 649 study of nivolumab, ipilimumab, and chemotherapy for gastric cancers.

Managing Adverse Events of Nivolumab/Chemotherapy for Gastric/GEJ Cancers

Targeted Oncology Staff

November 18th 2022

During a Targeted Oncology case-based roundtable event, Syma Iqbal, MD, discussed with participants their impressions of the CheckMate 649 chemoimmunotherapy regimen for patients with gastric/gastroesophageal junction cancers. This is the first of 2 articles based on this event.

PD-L1 CPS Plays Role in Selecting Treatment for Gastric Cancer

Targeted Oncology Staff

December 9th 2022

During a Targeted Oncology case-based roundtable event, Syma Iqbal, MD, discussed the addition of nivolumab to chemotherapy for patients with gastric/gastroesophageal junction cancer based on PD-L1 status. This is the second of 2 articles based on this event.